HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Severe hypoglycaemia after long-acting octreotide in a patient with an unrecognized malignant insulinoma.

Abstract
Insulinomas are the most common hormone-producing pancreatic neuroendocrine tumours (NETs), and patients usually present with symptoms secondary to hypoglycaemia. Octreotide has been widely used in the symptomatic treatment of patients with pancreatic NETs, including insulinomas. We describe a case of a patient with a metastatic NET, subsequently identified as a malignant insulinoma, who developed severe hypoglycaemia after treatment with long-acting octreotide.
AuthorsM L Healy, S J Dawson, R M L Murray, J Zalcberg, M Jefford
JournalInternal medicine journal (Intern Med J) Vol. 37 Issue 6 Pg. 406-9 (Jun 2007) ISSN: 1445-5994 [Electronic] Australia
PMID17535385 (Publication Type: Case Reports, Journal Article)
Chemical References
  • Delayed-Action Preparations
  • Octreotide
Topics
  • Adult
  • Delayed-Action Preparations (administration & dosage, adverse effects)
  • Humans
  • Hypoglycemia (chemically induced, diagnosis)
  • Insulinoma (diagnosis, drug therapy)
  • Male
  • Octreotide (administration & dosage, adverse effects)
  • Pancreatic Neoplasms (diagnosis, drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: